Xylem said revenue for Q1 2024 was $2,033 million, up 40% from $1,448 million a year earlier. On an organic basis, excluding the effects of acquisitions, divestitures and foreign exchange, it rose 7%.

1. 01

   Xylem said revenue for Q1 2024 was $2,033 million, up 40% from $1,448 million a year earlier. On an organic basis, excluding the effects of acquisitions, divestitures and foreign exchange, it rose 7%.

2. 02

   The company said net income for Q1 was $153 million, or $0.63 per share, and adjusted net income, which excludes restructuring costs, intangible amortization and other items, was $219 million, or $0.90 per share. It said its net income margin was 7.5%, up 70 basis points.

3. 03

   Xylem raised its full-year revenue outlook to about $8.5 billion, or up about 15 to 16% on a reported basis and up about 4 to 6% on an organic basis. That compares with its prior guidance of 14 to 15% on a reported basis and 3 to 5% on an organic basis. The company also raised its adjusted EPS outlook to $4.10 to $4.25 from $4.00 to $4.20.

4. 04

   The company said net cash from operating activities for Q1 2024 was $89 million ($(19) million a year earlier), capital expenditures were $74 million, and free cash flow, defined as the difference between the two, was $15 million ($(35) million a year earlier).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.